1.1Sulfur linkage to methyl
The scaffold bonds to sulfur, and sulfur bonds to the methyl carbon. The thioether retains a one-carbon terminal group and places a larger, more polarizable atom at the attachment point.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The scaffold bonds to sulfur, and sulfur bonds to the methyl carbon. The thioether retains a one-carbon terminal group and places a larger, more polarizable atom at the attachment point.
Fluorine occupies positions 2, 3, 5 and 6 on the phenyl ring, counting the scaffold attachment as position 1. The two fluorines next to the attachment flank the scaffold–aryl bond, and all four withdraw electron density through the ring's sigma bonds.
The rings share the bond between the two attachment carbons. A trans junction places the junction hydrogens on opposite faces and locks both rings in chair conformations.
Each designated substituent bond terminates in hydrogen. This leaves a smaller steric footprint at both attachment sites while preserving the scaffold's carbon connectivity.
The methylene carbon connects the phenyl ring to the R3 attachment point. The phenyl ring supplies a hydrophobic surface, and rotation about the methylene–phenyl bond lets that surface change orientation.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Rings of porcine pulmonary artery mount between a fixed hook and a force transducer in an oxygenated physiological buffer. The bath receives a contractile stimulus, followed by increasing concentrations of a formula (I) compound. The transducer records tension after each addition, and relaxation is expressed as a percentage of the tension generated by the contractile stimulus.
A protonated ethanolamine counterion replaces the inorganic metal ion at R5. One molar equivalent of ethanolamine is added to the free acid in aqueous ethanol to form the carboxylate salt. The solvent is removed under reduced pressure, and proton nuclear magnetic resonance measures the ratio of ethanolamine to the prostacyclin derivative.
A four-membered oxetane ring replaces the independent R1 and R2 substituents. The two scaffold carbons at those positions form one edge of the ring, and a methylene group and an ether oxygen complete the ring. An oxetane-containing intermediate carries both scaffold attachment points into the coupling step, and two-dimensional nuclear magnetic resonance verifies ring connectivity.
A solution of a formula (I) salt is divided into sealed 1 mL aliquots and held at 5, 25, and 40 °C. Aliquots from each temperature group are analyzed at 0, 24, and 72 hours using liquid chromatography with mass spectrometric detection. Calibration against the parent compound gives the percentage remaining at each time point, and additional chromatographic peaks track the appearance of degradation products.
An aqueous solution of a formula (I) salt fills the reservoir of a vibrating mesh nebulizer connected to a breathing simulator. The simulator draws aerosol through a collection filter during inspiration and routes exhaled flow through a separate outlet. Liquid chromatography measures the compound recovered from the inspiratory filter, and the recovered mass is divided by the number of simulated breaths.
A liquid handling robot dispenses serial dilutions of formula (I) compounds into wells containing cells that express the prostacyclin receptor. The plate includes vehicle controls and receptor-negative cells, and a plate reader measures intracellular cyclic adenosine monophosphate with a homogeneous fluorescence assay. Software subtracts the vehicle signal, fits a four-parameter logistic curve to each concentration series, and reports the half-maximal effective concentration and fitted maximum response.
R1 is ethynyl and R2 is hydrogen. The scaffold bonds directly to one carbon of the triple bond, and the other carbon bears a terminal hydrogen.
R is methoxy on a phenyl ring, with the methoxy group at position 4 relative to the ring's attachment to the rest of the molecule. The ring bonds to the methoxy oxygen, which in turn bonds to a methyl carbon.
R3 is acetyl and R4 is hydrogen. The acetyl group connects at the R3 position through its carbonyl carbon, which also bonds to a methyl group.
R5 is sodium in the carboxylate salt. One sodium ion balances the negative charge of each carboxylate group, and both ions become hydrated when the salt dissolves in water.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
in which R1 denotes unsubstituted or at least monosubstituted alkyl, alkenyl or alkynyl; unsubstituted or at least monosubstituted heteroalkyl, heteroalkenyl or heteroalkynyl; unsubstituted or at least monosubstituted cycloalkyl or cycloalkenyl; unsubstituted or at least monosubstituted heterocycloalkyl or heterocycloalkenyl; unsubstituted or at least monosubstituted-(alkylene)-cycloalkyl, -(alkenylene)-cycloalkyl, -(alkynylene)-cycloalkyl, -(alkylene)-cycloalkenyl, -(alkenylA · US 2009/0137573 A1 · ¶
R1 stands for a hydrogen radical, a C1-6-alkyl radical, a C1-6 alkoxy radical, a C2-6 hydroxyalkyl radical, a C2-6 alkenyl radical, a C2-6 alkynyl radical, a phenyl radical or for a C1-6-alkyl radical that is monosubstituted, disubstituted, or trisubstituted by a phenyl radical, R2 stands for a hydrogen radical, a C1-6-alkyl radical, a C1-6 alkoxy radical, a C2-6 hydroxyalkyl radical, a C2-6 alkenyl radical, a C2-6 alkynyl radical, a phenyl radical, a C1-6-alkyl radical monosB · US 7,951,815 B2 · ¶
If one or more of the substituents denote a cycloalkyl residue, heterocycloalkyl residue, cycloalkenyl residue or heterocycloalkenyl residue or comprise such a residue, which is mono- or polysubstituted, this may preferably be optionally substituted with 1, 2, 3, 4 or 5, particularly preferably with optionally 1, 2 or 3, substituents independently selected from the group consisting of F, Cl, Br, I, —CN, —CF3, —OH, —NH2, —O—CF3, —SH, —O—C1-5-alkyl, —O-phenyl, —O—CH2-phenyl, —(A · US 2009/0137573 A1 · ¶ 48
(CH2)-benzo[b]furanyl; —O-phenyl; —O-benzyl; phenyl; benzyl, naphthyl and —(CH2)-naphthyl, and each of the cyclic moieties of the —O-phenyl, —O-benzyl, phenyl, —(CH2)-benzo[b]furanyl, benzyl, naphthyl and —(CH2)—naphthyl groups optionally may be substituted by from 1 to 5 substituents independently selected from the group consisting of F, Cl, Br, —OH, —CF3, —SF5, —CN, —NO2, —OC1-5 alkyl, —C1-5 alkyl, —OCF3, —SCF3, phenyl, and —O-benzyl; wherein monosubstituted and polysubstitB · US 7,951,815 B2 · claim 1
(CH2)-benzo[b]furanyl; —O-phenyl; —O-benzyl; phenyl; benzyl, naphthyl and —(CH2)-naphthyl, and each of the cyclic moieties of the —O-phenyl, —O-benzyl, phenyl, —(CH2)-benzo[b]furanyl, benzyl, naphthyl and —(CH2)—naphthyl groups optionally may be substituted by from 1 to 5 substituents independently selected from the group consisting of F, Cl, Br, —OH, —CF3, —SF5, —CN, —NO2, —OC1-5 alkyl, —C1-5 alkyl, —OCF3, —SCF3, phenyl, and —O-benzyl; wherein monosubstituted and polysubstitB · US 7,951,815 B2 · claim 1
R2 denotes H; unsubstituted or at least monosubstituted alkyl, alkenyl or alkynyl; unsubstituted or at least monosubstituted heteroalkyl, heteroalkenyl or heteroalkynyl; unsubstituted or at least monosubstituted aryl; or unsubstituted or at least monosubstituted-(alkylene)-aryl, -(alkenylene)-aryl, -(alkynylene)-aryl; or R1 and R2 together with the nitrogen atom to which they are bound denote heterocycloalkyl or heterocycloalkenyl, which is unsubstituted or substituted with aA · US 2009/0137573 A1 · ¶
in which R1 denotes unsubstituted or at least monosubstituted alkyl, alkenyl or alkynyl; unsubstituted or at least monosubstituted heteroalkyl, heteroalkenyl or heteroalkynyl; unsubstituted or at least monosubstituted cycloalkyl or cycloalkenyl; unsubstituted or at least monosubstituted heterocycloalkyl or heterocycloalkenyl; unsubstituted or at least monosubstituted-(alkylene)-cycloalkyl, -(alkenylene)-cycloalkyl, -(alkynylene)-cycloalkyl, -(alkylene)-cycloalkenyl, -(alkenylA · US 2009/0137573 A1 · ¶
R3 represents hydrogen; a linear or branched unsubstituted or at least monosubstituted alkyl group which may comprise at least one heteroatom as a link; or a linear or branched unsubstituted or at least monosubstituted alkenyl group which may comprise at least one heteroatom as a link; a linear or branched unsubstituted or at least monosubstituted alkynyl group which may comprise at least one heteroatom as a link; an unsubstituted or at least monosubstituted aryl group or hetB · US 7,951,815 B2 · claim 1
R5 and R6 each independently are a linear or branched alkyl group; a linear or branched alkenyl group; or a linear or branched alkynyl group;B · US 7,951,815 B2 · claim 1
An empty cell means only that no passage was reproduced there.
There is a worldwide need for effective pain treatments.A · US 2009/0137573 A1 · ¶ 3
A particular object of the invention was to provide new compounds suitable for use in the treatment and/or inhibition of acute pain, chronic pain and/or neuropathic pain.A · US 2009/0137573 A1 · ¶ 7
There is thus a great need for suitable active pharmacological substances which inhibit reuptake of 5-hydroxytryptophane (serotonin) and are therefore particularly suitable for the therapy of obesity.B · US 7,951,815 B2 · ¶ 3
It is thus an object of the present invention to provide compounds which are particularly suitable for use as pharmaceutically active substances in medicinal drugs, preferably in medicinal drugs for the inhibition and/or treatment of obesity.B · US 7,951,815 B2 · ¶ 4
patent.fyi, US 2026/0355136 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355136/, SHA-256 5f4c3a9a4b8a9c021579d84dd9c445aa41da3756c1ceb6808b8e6fced886a5b2